Important Safety Notice
The FDA has required Sanofi US to distribute this safety notice to your organization as part of their AFREZZA REMS (Risk Evaluation and Mitigation Strategy) program. We request that you inform your members about the following serious risks of AFREZZA:

- Risk of acute bronchospasm in patients with chronic lung disease
- Contraindicated in patients with chronic lung disease as asthma or COPD
- Need to evaluate patients for lung disease before starting AFREZZA

Before initiating AFREZZA, perform
  - a detailed medical history
  - physical examination, and
  - spirometry (FEV1)

A non-promotional factsheet, reviewed by the FDA, with more detailed safety information on these risks, and a link to the Prescribing Information including the BOXED WARNING are available at www.AfrezzaREMS.com.
**Indication**
AFREZZA (insulin human) Inhalation Powder is a rapid acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

**Important limitations of use**
- Not a substitute for long-acting insulin. In patients with type 1 diabetes, must use with a long-acting insulin
- Not recommended for the treatment of diabetic ketoacidosis
- Not recommended in patients who smoke or have recently stopped smoking

This email does not contain the complete safety profile of AFREZZA. To review the Prescribing Information and Medication Guide, see links below:

**Prescribing information**
**Medication Guide**

Please visit [www.AfrezzaREMS.com](http://www.AfrezzaREMS.com) for more information.

**Reporting Adverse Events**
You are encouraged to report negative side effects of prescription drugs to Sanofi US at 1-800-633-1610 and/or the FDA [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

Signature,

Charles Hugh-Jones, M.D.
Vice President and Chief Medical Officer, North America Pharmaceuticals
Sanofi US